High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study.
High Complete Response Rate in Patients With Metastatic Renal Cell Carcinoma Receiving Autologous Cytokine-Induced Killer Cell Therapy Plus Anti-Programmed Death-1 Agent: A Single-Center Study.
复制标题
接受自体 CIK 加 PD-1 药物的 mRCC 患者的高完全缓解率：单中心研究
DOI：
10.3389/fimmu.2021.779248
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Gao Q
中科院分区：
文献类型：
--
作者：
Zhao L;Li T;Song Y;Yang Y;Ma B;Zhang Y;Shang Y;Xu B;Guo J;Qin P;Han L;Fu X;Lin H;Liu L;Ren X;Wang Z;Gao Q
CheckMate 025试验的结果确立了nivolumab在转移性肾细胞癌（mRCC）二线治疗中的地位，客观缓解率（ORR）为25%，完全缓解率（CR）为1%。因此，抗程序性死亡（PD）-1抗体在mRCC二线治疗中的疗效需要改善。本研究旨在探讨抗PD-1药物联合CIK细胞治疗难治性肾细胞癌的临床疗效和安全性。本研究纳入了既往靶向治疗难治性mRCC患者。所有患者均接受抗PD-1 + CIK细胞治疗。评估ORR和CR率、无进展生存期（PFS）、总生存期（OS）和安全性。在29例患者中的7例中观察到CR，在5例患者中观察到部分缓解。ORR为41.4%，中位PFS为15.0个月。截至末次随访，15例患者死亡，平均生存时间为37个月。在达到CR的患者中，1例在停药后18.8个月发生小脑转移，但在局部伽玛刀和1个月阿西替尼治疗后再次达到CR。该方案耐受性良好，无治疗相关死亡。抗PD-1和CIK细胞疗法的联合治疗在既往靶向治疗难治的mRCC患者中是安全有效的。高CR率和长期无病生存期，即使在长期停止治疗后，表明这种联合治疗可能代表这种类型的恶性肿瘤的潜在治愈方案。
The results of the CheckMate 025 trial established the status of nivolumab in the second-line treatment of metastatic renal cell carcinoma (mRCC), with an objective response rate (ORR) of 25% and a complete response (CR) rate of 1%. Thus, the efficacy of anti-programmed death (PD)-1 antibodies in the second-line treatment of mRCC requires improvement. The purpose of this study was to explore the clinical efficacy and safety of anti-PD-1 agents combined with cytokine-induced killer (CIK) cell therapy for refractory mRCC. Patients with mRCC refractory to previous targeted therapy were included in this study. All patients received anti-PD-1 plus CIK cell therapy. The ORR and CR rate, progression-free survival (PFS), overall survival (OS), and safety were assessed. CR was observed in seven of the 29 patients, and partial response was observed in five patients. The ORR was 41.4% and the median PFS was 15.0 months. Up to the last follow-up, 15 patients died with an average survival time of 37 months. Among the patients who achieved a CR, one experienced cerebellar metastasis 18.8 months after discontinuation, but achieved CR again after localized gamma knife and 1-month axitinib treatment. This regimen was tolerated well and there was no treatment-related death. Combination therapy with anti-PD-1 and CIK cell therapy is safe and effective in patients with mRCC refractory to previous targeted therapy. The high CR rate and long disease-free survival even after long-term discontinued therapy suggest that this combination treatment may represent a potential curative regimen for this type of malignancy.
登录
查看更多内容
自体细胞因子诱导杀伤 (CIK) 细胞增强晚期非小细胞肺癌患者对 PD-1 阻断抗体的临床反应：一项初步研究
影响因子：
2.9
作者：
Han Y;Mu D;Liu T;Zhang H;Zhang J;Li S;Wang R;Du W;Hui Z;Zhang X;Ren X
通讯作者：
Ren X
影响因子：
168.9
作者：
Rini, Brian I.;Powles, Thomas;Motzer, Robert J.
通讯作者：
Motzer, Robert J.
DOI：
10.1056/nejmoa1510665
发表时间：
2015-11-05
期刊：
The New England journal of medicine
影响因子：
--
作者：
Motzer RJ;Escudier B;McDermott DF;George S;Hammers HJ;Srinivas S;Tykodi SS;Sosman JA;Procopio G;Plimack ER;Castellano D;Choueiri TK;Gurney H;Donskov F;Bono P;Wagstaff J;Gauler TC;Ueda T;Tomita Y;Schutz FA;Kollmannsberger C;Larkin J;Ravaud A;Simon JS;Xu LA;Waxman IM;Sharma P;CheckMate 025 Investigators
通讯作者：
CheckMate 025 Investigators
影响因子：
4.1
作者：
Han L;Shang YM;Song YP;Gao QL
通讯作者：
Gao QL
影响因子：
64.8
作者：
Herbst RS;Soria JC;Kowanetz M;Fine GD;Hamid O;Gordon MS;Sosman JA;McDermott DF;Powderly JD;Gettinger SN;Kohrt HE;Horn L;Lawrence DP;Rost S;Leabman M;Xiao Y;Mokatrin A;Koeppen H;Hegde PS;Mellman I;Chen DS;Hodi FS
通讯作者：
Hodi FS